Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Proteus Digital Health Makes Appointments

This article was originally published in Scrip

Executive Summary

Proteus Digital Health, a company creating a new category of therapy known as digital medicines, has appointed Molly O'Neill chief commercial officer (CMO), Shumeet Banerji to its board of directors and Jonathan Symonds as chair. O'Neill brings 30 years of experience to Proteus and is joining from Tenet Health, where she was vice president of business development. Symonds is currently chair of HSBC Bank Plc., chair of the supervisory board of Innocoll AG and non-executive director of Genomics England. Previously he was chief financial officer (CFO) of Novartis, partner and managing director of Goldman Sachs and CFO of AstraZeneca Plc. Banerji is founder and partner of Condorcet, an investment and advisory firm, and he retired from Booz & Company Inc. having served as its founding CEO. He previously held leadership roles at Allen & Hamilton in India, UK and globally. Currently he serves on the board of HP, Inc. and Innocoll, AG.

You may also be interested in...

Text Mining And Machine Reading: The Answer To Pharma's R&D Data Mountain?

How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.

Adherence Issues Add Weight To Digital Trials Push

Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.

Appointments: Five Prime, Depomed, Gilead, Arix Bioscience and Corbus

This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts